


Revizinone

Chemical Properties

CAS No. :	133718-29-3
Formula:	C ₂₆ H ₂₉ N ₅ O ₃
Molecular Weight:	459.54
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Revizinone, a novel selective phosphodiesterase inhibitor, exhibits an IC ₅₀ value of 0.036 microM on this enzyme.
Targets(IC ₅₀)	Others,PDE
In vitro	Revizinone significantly increased global LV function and systolic wall thickening in ischemic areas at doses greater than or equal to 0.16 mg/kg i.v. The administration of Revizinone improved the hemodynamic profile with an increase in cardiac output, a decrease in systemic vascular resistance, and a stable heart rate and mean arterial blood pressure. With regard to the reconstitution of contractility and cardiac function Revizinone (E-isomer) was 10 fold more potent than R 79595 and nearly 100 fold more potent than R 80123 (Z-isomer) [1] [2][4].

Solubility Information

Solubility	DMSO: 4.6 mg/mL (10.01 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1761 mL	10.8804 mL	21.7609 mL
5 mM	0.4352 mL	2.1761 mL	4.3522 mL
10 mM	0.2176 mL	1.088 mL	2.1761 mL
50 mM	0.0435 mL	0.2176 mL	0.4352 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Herregods L et al. Haemodynamic effects of R 80122 immediately after cardiopulmonary bypass; preliminary results. *Anaesthesia*. 1994 Aug;49(8):719-22.
- Schneider J et al. Cardiac effects of R 79595 and its isomers (R 80122 and R 80123) in an acute heart failure model. A new class of cardiotonic agents with highly selective phosphodiesterase III inhibitory properties. *Naunyn Schmiedebergs Arch Pharmacol*. 1992 Nov;346(5):563-72.
- de Cheffoy de Courcelles D et al. Inhibition of human cardiac cyclic AMP-phosphodiesterases by R 80122, a new selective cyclic AMP-phosphodiesterase III inhibitor: a comparison with other cardiotonic compounds. *J Pharmacol Exp Ther*. 1992 Oct;263(1):6-14.
- Vandeplassche GM et al. Comparative effects of R 80122, enoximone, and milrinone on left ventricular phosphodiesterase isoenzymes in vitro and on contractility of normal and stunned myocardium in vivo in dogs. *J Cardiovasc Pharmacol*. 1992 May;19(5):714-22.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481